Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Biologics Outsourcing Market In 2029?

The size of the biologics outsourcing market has seen a quick expansion in the last few years. It is predicted to increase from $20.06 billion in 2024 to $22.58 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. The notable growth during the historical period is due to rising research and development expenses, regulatory strains, the necessity for specialized skills, and globalization.

Expectations are high for robust growth in the biologics outsourcing market in the upcoming years, with projections indicating a rise to$37.28 billion in 2029″ and a compound annual growth rate (CAGR) of 13.4%. Factors contributing to this predicted growth during the forecast period include the expansion of emerging markets, the progression of personalized medicine, strategic alliances, and the expiration of biological drug patents. Technological advances, a mounting intricacy in outsourcing, the growth of the biosimilars market, the integration of data analytics and the resilience of the supply chain are some of the primary trends anticipated during this period.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What are the Fundamental Drivers and Innovations Shaping the Biologics Outsourcing Market?

The increase in cancer incidences is anticipated to drive the biologics outsourcing market’s expansion in the future. Cancer is a collective term for a range of diseases that can occur in nearly any part of the body when rogue cells grow beyond control, break their usual boundaries, and either spread to other organs or attack surrounding body parts. Biologics outsourcing contributes significantly towards cancer situations by offering specific expertise, resources, and infrastructure for the development, production, and clinical supply of biologic therapies. These therapies include monoclonal antibodies, immunotherapies, and other targeted biologics, which are a crucial aspect of diagnosing, treating, and managing different cancer types. For example, the National Center for Biotechnology Information, a US intergovernmental organization, recorded 1,958,310 new cancer cases in the United States in January 2023, with an estimated 609,820 cancer deaths expected in 2023. Additionally, the annual number of new cancer cases is projected to reach 29.5 million, with cancer-related deaths increasing to 16.4 million by 2040. As such, the escalating number of cancer cases is fueling the growth of the biologics outsourcing market.

How Is the Biologics Outsourcing Market Segmented?

The biologics outsourcingmarket covered in this report is segmented –

1) By Product Type: Antibodies; Recombinant; Vaccines; Protein; Other Products

2) By Source: Human; Microbial; Other Source

3) By Application: Oncology; Cellular And Gene Therapy; Blood And Blood-Related Products Development; Vaccine Development; Stem Cell Research; Other Applications

4) By End User: Pharmaceutical Industries; Biotechnology Industries; Contract Development And Manufacturing Organization(CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins; Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines; Preventive Vaccines

4) By Protein: Enzymes; Hormones; Cytokines

5) By Other Products: Gene Therapies; Cell Therapies; Biosimilars

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Which Regions Are Driving the Next Phase of the Biologics Outsourcing Market Growth?

North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Biologics Outsourcing Market?

Biologics advancements are an emerging trend garnering attention in the biologics outsourcing sector. Main corporations active in this market are embracing innovative technologies to maintain their market standing. To exemplify, Abzena, a US contract development and manufacturing organization (CDMO), Alira Health, a US healthcare outfit, and Oncodesign, a biopharmaceutical firm from France, unveiled DRIVE-Biologics in February 2022. This is a consortium devoted to biologic drug exploration and evolution programs. It offers combined solutions with expert services, starting from biological discovery to clinical and business manufacturing. This collaboration infuses industry supremacy in areas like design and developability, preclinical pharmacology and pharmaco-imaging evidence, toxicology, and commercial manufacturing clinical design. It simplifies data exchange and program outputs to aid in minimizing biologics development risks. Moreover, the partners will be privy to knowhow at all stages of drug discovery and development, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

View the full report here:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

How Is the Biologics Outsourcing Market Defined and What Are Its Core Parameters?

Biologics outsourcing refers to pharmaceutical companies partnering with external vendors or contract manufacturing organizations (CMOs) to outsource various aspects of biologic drug development, manufacturing, and supply chain management. This is used in the pharmaceutical industry for different purposes related to biological drug development, manufacturing, and supply chain management.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model